|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bade B and Dela Cruz C: Lung cancer 2020:
Epidemiology, etiology, and prevention. Clin Chest Med. 41:1–24.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schuller HM: The impact of smoking and the
influence of other factors on lung cancer. Expert Rev Respir Med.
13:761–769. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rivera GA and Wakelee H: Lung cancer in
never smokers. Adv Exp Med Biol. 893:43–57. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jones GS and Baldwin DR: Recent advances
in the management of lung cancer. Clin Med (Lond). 18 (Suppl
2):S41–S46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Steven A, Fisher SA and Robinson BW:
Immunotherapy for lung cancer. Respirology. 21:821–833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim D, Lee YS, Kim DH and Bae SC: Lung
cancer staging and associated genetic and epigenetic events. Mol
Cells. 43:1–9. 2020.PubMed/NCBI
|
|
8
|
Skřičková J, Kadlec B, Venclíček O and
Merta Z: Lung cancer. Cas Lek Cesk. 157:226–236. 2018.
|
|
9
|
Wang Y, Huang J, Li B, Xue H, Tricot G, Hu
L, Xu Z, Sun X, Chang S, Gao L, et al: A small-molecule inhibitor
targeting TRIP13 suppresses multiple myeloma progression. Cancer
Res. 80:536–548. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ye Q, Rosenberg S, Moeller A, Speir J, Su
T and Corbett K: TRIP13 is a protein-remodeling AAA+ ATPase that
catalyzes MAD2 conformation switching. Elife. 4:e073672015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clairmont CS, Sarangi P, Ponnienselvan K,
Galli LD, Csete I, Moreau L, Adelmant G, Chowdhury D, Marto JA and
D'Andrea AD: TRIP13 regulates DNA repair pathway choice through
REV7 conformational change. Nat Cell Biol. 22:87–96. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yost S, de Wolf B, Hanks S, Zachariou A,
Marcozzi C, Clarke M, de Voer R, Etemad B, Uijttewaal E, Ramsay E,
et al: Biallelic TRIP13 mutations predispose to Wilms tumor and
chromosome missegregation. Nat Genet. 49:1148–1151. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma HT and Poon RYC: TRIP13 regulates both
the activation and inactivation of the spindle-assembly checkpoint.
Cell Rep. 14:1086–1099. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tao Y, Yang G, Yang H, Song D, Hu L, Xie
B, Wang H, Gao L, Gao M, Xu H, et al: TRIP13 impairs mitotic
checkpoint surveillance and is associated with poor prognosis in
multiple myeloma. Oncotarget. 8:26718–26731. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yao J, Zhang X, Li J, Zhao D, Gao B, Zhou
H, Gao S and Zhang L: Silencing TRIP13 inhibits cell growth and
metastasis of hepatocellular carcinoma by activating of
TGF-β1/smad3. Cancer Cell Int. 18:2082018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ju L, Li X, Shao J, Lu R, Wang Y and Bian
Z: Upregulation of thyroid hormone receptor interactor 13 is
associated with human hepatocellular carcinoma. Oncol Rep.
40:3794–3802. 2018.PubMed/NCBI
|
|
17
|
Sheng N, Yan L, Wu K, You W, Gong J, Hu L,
Tan G, Chen H and Wang Z: TRIP13 promotes tumor growth and is
associated with poor prognosis in colorectal cancer. Cell Death
Dis. 9:4022018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao Y, Liu S, Guo Q, Zhang S, Zhao Y, Wang
H, Li T, Gong Y, Wang Y, Zhang T, et al: Increased expression of
TRIP13 drives the tumorigenesis of bladder cancer in association
with the EGFR signaling pathway. Int J Biol Sci. 15:1488–1499.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dong L, Ding H, Li Y, Xue D, Li Z, Liu Y,
Zhang T, Zhou J and Wang P: TRIP13 is a predictor for poor
prognosis and regulates cell proliferation, migration and invasion
in prostate cancer. Int J Biol Macromol. 121:200–206. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Q, Dong Y, Hao S, Tong Y, Luo Q and
Aerxiding P: The oncogenic role of TRIP13 in regulating
proliferation, invasion, and cell cycle checkpoint in NSCLC cells.
Int J Clin Exp Pathol. 12:3357–3366. 2019.PubMed/NCBI
|
|
21
|
Mittal V: Epithelial mesenchymal
transition in tumor metastasis. Annu Rev Pathol. 13:395–412. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yeung KT and Yang J:
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol.
11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saitoh M: Involvement of partial EMT in
cancer progression. J Biochem. 164:257–264. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang G, Zhu Q, Fu G, Hou J, Hu X, Cao J,
Peng W, Wang X, Chen F and Cui H: TRIP13 promotes the cell
proliferation, migration and invasion of glioblastoma through the
FBXW7/c-MYC axis. Br J Cancer. 121:1069–1078. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu MX, Wei CY, Zhang PF, Gao DM, Chen J,
Zhao Y, Dong SS and Liu BB: Elevated TRIP13 drives the AKT/mTOR
pathway to induce the progression of hepatocellular carcinoma via
interacting with ACTN4. J Exp Clin Cancer Res. 38:4092019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alfieri C, Chang L, Zhang Z, Yang J,
Maslen S, Skehel M and Barford D: Molecular basis of APC/C
regulation by the spindle assembly checkpoint. Nature. 536:431–436.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alfieri C, Chang L and Barford D:
Mechanism for remodelling of the cell cycle checkpoint protein MAD2
by the ATPase TRIP13. Nature. 559:274–278. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ye Q, Kim D, Dereli I, Rosenberg SC,
Hagemann G, Herzog F, Tóth A, Cleveland DW and Corbett KD: The AAA+
ATPase TRIP13 remodels HORMA domains through N-terminal engagement
and unfolding. EMBO J. 36:2419–2434. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu S, Qian J, Guo M, Gu C and Yang Y:
Insights into a crucial role of TRIP13 in human cancer. Comput
Struct Biotechnol J. 17:854–861. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu S, Guo M, Fan Z, Chen Y, Shi X, Gu C
and Yang Y: Elevated TRIP13 drives cell proliferation and drug
resistance in bladder cancer. Am J Transl Res. 11:4397–4410.
2019.PubMed/NCBI
|
|
33
|
Lu W and Kang Y: Epithelial-mesenchymal
plasticity in cancer progression and metastasis. Dev Cell.
49:361–374. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Venhuizen J, Jacobs F, Span P and Zegers
M: P120 and E-cadherin: Double-edged swords in tumor metastasis.
Semin Cancer Biol. 60:107–120. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Strouhalova K, Přechová M, Gandalovičová
A, Brábek J, Gregor M and Rosel D: Vimentin intermediate filaments
as potential target for cancer treatment. Cancers (Basel).
12:1842020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie Q, Zhu Z, He Y, Zhang Z, Zhang Y, Wang
Y, Luo J, Peng T, Cheng F, Gao J, et al: A lactate-induced
Snail/STAT3 pathway drives GPR81 expression in lung cancer cells.
Biochim Biophys Acta Mol Basis Dis. 1866:1655762020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Agarwal S, Behring M, Kim HG,
Chandrashekar DS, Chakravarthi BVSK, Gupta N, Bajpai P, Elkholy A,
Al Diffalha S, Datta PK, et al: TRIP13 promotes metastasis of
colorectal cancer regardless of p53 and microsatellite instability
status. Mol Oncol. 14:3007–3029. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kurita K, Maeda M, Mansour MA, Kokuryo T,
Uehara K, Yokoyama Y, Nagino M, Hamaguchi M and Senga T: TRIP13 is
expressed in colorectal cancer and promotes cancer cell invasion.
Oncol Lett. 12:5240–5246. 2016. View Article : Google Scholar : PubMed/NCBI
|
